top of page

Biopharma Daily Stock Updates - 03/03/22

$XBI $86.65| -2.99%


 

Pipeline Updates

$GLSI -3.3% Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting source


$IMAB -11.3% I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer source


$TGTX -9.5% TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL source


$ARAV +2.8% Aravive Announces Positive Updated Data and New Biomarker Data from Phase 1b Study of Batiraxcept in Clear Cell Renal Cell Carcinoma source


$TNXP +33.1% Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome source


$FULC +5.4% Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) source


Business Updates

$AQST +4.8% Aquestive Therapeutics And Haisco Pharmaceutical Group Enter Licensing And Supply Agreement For Riluzole Oral Film For ALS Treatment In China source


$BBIO -4.5% helsinn group and bridgebio pharma announce update to strategic collaboration to develop, manufacture and commercialize infigratinib in oncology indications in the u.s. source



 

Posted by JM

0 comments

Kommentare


bottom of page